Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.

@article{Offidani2004ThalidomidePO,
  title={Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.},
  author={Massimo Offidani and Laura Corvatta and Monica Marconi and Attilio Olivieri and Massimo Catarini and Anna Mele and Marino Brunori and Marco Candela and Lara Malerba and Debora Capelli and Mauro Montanari and Pietro Leoni},
  journal={The hematology journal : the official journal of the European Haematology Association},
  year={2004},
  volume={5 4},
  pages={
          312-7
        }
}
Thalidomide, the prototype of a new class of agents active against multiple myeloma (MM), exerts synergistic/additive effects when combined with other drugs. The aim of this study was to compare the toxicity and efficacy of thalidomide alone and in combination with oral melphalan. Patients with advanced MM received 100 mg/day oral thalidomide escalated weekly up to 600 mg/day (n=23; T group), alone or with 0.20 oral mg/kg/die melphalan administered monthly for four consecutive days (n=27; TM… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Thalidomide for treatment of multiple myeloma: 10 years later.

Antonio Palumbo, Thierry Facon, +8 authors Jean-Luc Harousseau
  • Blood
  • 2008

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

A study of the safety and efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study (abstract)

H Oakervee, H Baugh, +3 authors C Williams
  • Br J Haematol
  • 2002

Thalidomide combined with vincristine , adriamycin and dexamethasone ( TVAD ) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting ( abstract )

J Cavenagh
  • Blood
  • 2002